As of the latest Form 4 filed Jun 11, 2026.
What Kalvista Pharmaceuticals Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 42 most recent filings for KALV.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-11 | 2026-06-11 | Audhya Paul K. CHIEF MEDICAL OFFICER | DDisposition | −150K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-11 | Sweeny Nicole Chief Commercial Officer | DDisposition | −59.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-11 | Piekos Brian Chief Financial Officer | DDisposition | −21.7K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-11 | Yea Christopher CHIEF DEVELOPMENT OFFICER | DDisposition | −230K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-11 | 2026-06-11 | Palleiko Benjamin L CHIEF EXECUTIVE OFFICER | DDisposition | −480K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-05-29 | 2026-05-27 | Yea Christopher CHIEF DEVELOPMENT OFFICER | SSale | −33.8K | $26.78 | $905K | No | Form 4 ↗ |
| 2026-05-29 | 2026-05-27 | Yea Christopher, CHIEF DEVELOPMENT OFFICER | MExercise | +33.8K | $7.07 | $239K | No | Form 4 ↗ |
| 2026-05-27 | 2026-05-26 | Audhya Paul K. CHIEF MEDICAL OFFICER | SSale | −2.24K | $26.78 | $60.0K | No | Form 4 ↗ |
| 2026-05-27 | 2026-05-26 | Sweeny Nicole Chief Commercial Officer | SSale | −1.49K | $26.78 | $39.9K | No | Form 4 ↗ |
| 2026-05-27 | 2026-05-26 | Yea Christopher CHIEF DEVELOPMENT OFFICER | SSale | −1.97K | $26.78 | $52.6K | No | Form 4 ↗ |
| 2026-05-27 | 2026-05-22 | Audhya Paul K. CHIEF MEDICAL OFFICER | MExercise | +5.00K | — | — | No | Form 4 ↗ |
| 2026-05-27 | 2026-05-22 | Sweeny Nicole Chief Commercial Officer | MExercise | +5.00K | — | — | No | Form 4 ↗ |
| 2026-05-27 | 2026-05-22 | Yea Christopher CHIEF DEVELOPMENT OFFICER | MExercise | +3.13K | — | — | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-22 | Audhya Paul K. CHIEF MEDICAL OFFICER | SSale | −2.69K | $26.78 | $71.9K | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-22 | Sweeny Nicole Chief Commercial Officer | SSale | −1.86K | $26.78 | $49.8K | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-22 | Piekos Brian Chief Financial Officer | SSale | −1.49K | $26.78 | $39.9K | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-22 | Yea Christopher CHIEF DEVELOPMENT OFFICER | SSale | −2.36K | $26.78 | $63.2K | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-22 | Palleiko Benjamin L CHIEF EXECUTIVE OFFICER | SSale | −10.9K | $26.78 | $293K | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Audhya Paul K. CHIEF MEDICAL OFFICER | MExercise | +6.25K | — | — | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Sweeny Nicole Chief Commercial Officer | MExercise | +6.25K | — | — | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Piekos Brian Chief Financial Officer | MExercise | +5.00K | — | — | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Yea Christopher CHIEF DEVELOPMENT OFFICER | MExercise | +3.75K | — | — | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Palleiko Benjamin L CHIEF EXECUTIVE OFFICER | MExercise | +23.3K | — | — | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-12 | Palleiko Benjamin L CHIEF EXECUTIVE OFFICER | SSale | −3.32K | $26.71 | $88.7K | No | Form 4 ↗ |
| 2026-05-13 | 2026-05-11 | Palleiko Benjamin L, CHIEF EXECUTIVE OFFICER | MExercise | +7.12K | — | — | No | Form 4 ↗ |
| 2026-04-20 | 2026-04-17 | Audhya Paul K. CHIEF MEDICAL OFFICER | SSale | −2.69K | $20.22 | $54.3K | No | Form 4 ↗ |
| 2026-04-20 | 2026-04-17 | Sweeny Nicole Chief Commercial Officer | SSale | −1.86K | $20.22 | $37.6K | No | Form 4 ↗ |
| 2026-04-20 | 2026-04-17 | Piekos Brian Chief Financial Officer | SSale | −1.86K | $20.22 | $37.6K | No | Form 4 ↗ |
| 2026-04-20 | 2026-04-17 | Palleiko Benjamin L CHIEF EXECUTIVE OFFICER | SSale | −9.55K | $20.22 | $193K | No | Form 4 ↗ |
| 2026-04-20 | 2026-04-16 | Audhya Paul K. CHIEF MEDICAL OFFICER | MExercise | +6.25K | — | — | No | Form 4 ↗ |
| 2026-04-20 | 2026-04-16 | Sweeny Nicole Chief Commercial Officer | MExercise | +6.25K | — | — | No | Form 4 ↗ |
| 2026-04-20 | 2026-04-16 | Piekos Brian Chief Financial Officer | MExercise | +6.25K | — | — | No | Form 4 ↗ |
| 2026-04-20 | 2026-04-16 | Palleiko Benjamin L CHIEF EXECUTIVE OFFICER | MExercise | +20.3K | — | — | No | Form 4 ↗ |
| 2026-03-27 | 2026-03-26 | Venrock Healthcare Capital Partners III, L.P. 10% owner | SSale | −3.18K | $19.12 | $60.9K | No | Form 4 ↗ |
| 2026-03-27 | 2026-03-26 | Venrock Healthcare Capital Partners III, L.P., 10% owner | SSale | −15.4K | $18.82 | $290K | No | Form 4 ↗ |
| 2026-03-27 | 2026-03-26 | Venrock Healthcare Capital Partners III, L.P., 10% owner | SSale | −21.4K | $17.76 | $380K | No | Form 4 ↗ |
| 2026-03-27 | 2026-03-25 | Venrock Healthcare Capital Partners III, L.P., 10% owner | SSale | −160.00 | $17.53 | $2.80K | No | Form 4 ↗ |
| 2026-03-27 | 2026-03-25 | Venrock Healthcare Capital Partners III, L.P., 10% owner | SSale | −174K | $16.95 | $2.96M | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-09 | Palleiko Benjamin L CHIEF EXECUTIVE OFFICER | SSale | −6.69K | $16.08 | $108K | No | Form 4 ↗ |
| 2026-03-10 | 2026-03-06 | Palleiko Benjamin L, CHIEF EXECUTIVE OFFICER | MExercise | +15.6K | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Palleiko Benjamin L CHIEF EXECUTIVE OFFICER | SSale | −3.35K | $15.70 | $52.7K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Palleiko Benjamin L, CHIEF EXECUTIVE OFFICER | MExercise | +7.12K | — | — | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also KALV’s full analysis or the market-wide insider trading feed. The tabs above jump to KALV’s other SEC data.
Source: SEC Form 4 filings for KALV, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.